Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
0(0%)
Results Posted
114%(8 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_1
1
11%
Ph phase_3
2
22%
Ph phase_2
1
11%
Ph phase_4
5
56%

Phase Distribution

1

Early Stage

1

Mid Stage

7

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
1(11.1%)
Phase 3Large-scale testing
2(22.2%)
Phase 4Post-market surveillance
5(55.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

77.8%

7 of 9 finished

Non-Completion Rate

22.2%

2 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(7)
Terminated(2)

Detailed Status

Completed7
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
87.5%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (11.1%)
Phase 21 (11.1%)
Phase 32 (22.2%)
Phase 45 (55.6%)

Trials by Status

completed778%
terminated111%
withdrawn111%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_4

Vorapaxar on Thrombin Generation and Coagulability

NCT03207451
completedphase_4

Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor

NCT02545933
completedphase_4

Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus

NCT02548650
completedphase_4

Vorapaxar in the Human Endotoxemia Model

NCT02875028
completedphase_1

Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints

NCT02394730
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT03207451Phase 4

Vorapaxar on Thrombin Generation and Coagulability

Completed
NCT02545933Phase 4

Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor

Completed
NCT02548650Phase 4

Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus

Completed
NCT02875028Phase 4

Vorapaxar in the Human Endotoxemia Model

Completed
NCT02394730Phase 1

Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints

Completed
NCT00526474Phase 3

Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)

Completed
NCT00527943Phase 3

Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736)

Terminated
NCT02975583Phase 4

Vorapaxar and Lower Extremity Bypass Grafts

Withdrawn
NCT00684203Phase 2

Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9